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Abstract: Idiopathic intracranial hypertension (IIH) results in raised intracranial pressure (ICP) 
leading to papilledema, visual dysfunction, and headaches. Obese females of reproductive age 
are predominantly affected, but the underlying pathological mechanisms behind IIH remain 
unknown. This review provides an overview of pathogenic factors that could result in IIH with 
particular focus on hormones and the impact of obesity, including its role in neuroendocrine 
signaling and driving inflammation. Despite occurring almost exclusively in obese women, there 
have been a few studies evaluating the mechanisms by which hormones and adipokines exert 
their effects on ICP regulation in IIH. Research involving 11β-hydroxysteroid dehydrogenase 
type 1, a modulator of glucocorticoids, suggests a potential role in IIH. Improved understanding 
of the complex interplay between adipose signaling factors such as adipokines, steroid hormones, 
and ICP regulation may be key to the understanding and future management of IIH.
Keywords: 11beta-hydroxysteroid dehydrogenase type 1, steroid and adipokines, obesity, leptin
Introduction
Idiopathic intracranial hypertension (IIH), previously known as benign intracranial 
hypertension or pseudotumor cerebri, is a disabling condition of predominantly young, 
obese women of childbearing age. The condition results in raised ICP, of no known 
cause, resulting in visual loss, headaches, and papilledema. IIH without papilledema 
can also occur but is rare and not the focus of this review.
IIH affects 0.5–2 per 100,000 annually in the general population1,2 but increases 
to 12–20 per 100,000 for obese women of reproductive age.1–4 Female sex and obesity 
are strongly associated with the condition. In a cohort of 721 IIH patients, 91% were 
reported as female5 with 70%–88% being obese.6,7
A diagnosis of IIH is made using the updated modified Dandy criteria. This is 
based on the presence of papilledema, with an absence of secondary causes and raised 
cerebrospinal fluid (CSF) pressure .25 cm CSF, measured by lumbar puncture in the 
lateral decubitus.8 The current management options for the condition are limited and 
include disease modification to promote weight loss and acetazolamide, but other 
diuretics may also be used. Surgical management varies although it mainly involves 
CSF shunting or sometimes optic nerve sheath fenestration and remains reserved for 
rapid or progressive loss of vision. Venous sinus stenting is used in some specialist 
centers although long-term efficacy data are awaited.
The etiology of this debilitating condition remains undetermined. Dysregula-
tion of CSF dynamics is key and may involve hypersecretion of CSF at the choroid 
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plexus, reduced drainage at the arachnoid granulations and/
or lymphatics, and aberrant venous pressure gradients.9 It is 
unlikely that a single anatomical location for CSF dysregula-
tion is exclusively responsible for the raised ICP in IIH, and 
multiple sites and mechanisms may be involved in impairing 
ICP homeostasis. As .70% of patients with the condition are 
obese, adiposity is felt to have a causative role in IIH, but the 
mechanisms by which obesity predisposes to the condition 
have not been fully elucidated.
Human fat is an active endocrine tissue, secreting a 
myriad of neuroendocrine molecules that could potentially 
play a role in IIH. Given the very strong female preponder-
ance, steroid hormones are also likely to be involved.
This review provides an overview of the potential role of 
hormones, adipokines, and cytokines in IIH and describes 
new potential pathogenic mechanisms in this disease.
Obesity
Role of weight
Obesity is a predominant phenotype in IIH patients. A pro-
spective study from the USA determined the occurrence of 
IIH among 1,084 obese women being evaluated for bariatric 
surgery (mean body mass index [BMI] 47.9 kg/m2). Seven 
patients were diagnosed with IIH suggesting an annual 
incidence in this population as high as 323 per 100,000.10 
Similar results were reported by Daniels et al, who found that 
higher BMIs were associated with an increasingly greater risk 
of IIH.11 In the same study, weight gain within the 12 months 
prior to symptom onset was investigated, and this analysis 
showed that a recent weight gain was also strongly associ-
ated with the development of IIH. Interestingly, both previ-
ously obese and nonobese (BMI ,30 kg/m2) patients who 
experienced a relatively moderate weight gain of 5%–15% 
had a similar increased risk of IIH.11 The fact that IIH can 
be triggered by weight gain implies a role for adiposity in 
disease development.
The importance of obesity in IIH etiology is further dem-
onstrated by the role of weight loss in treating the underlying 
disease. Weight loss has proven to be effective for reducing 
ICP and improving visual outcomes for patients in several 
clinical studies, both employing calorie restriction12–14 and 
gastric surgeries.15,16 Additionally, a retrospective study 
found that minor weight loss of only ∼6% led to a greater 
resolution in papilledema than those patients treated with 
acetazolamide alone.17 Taken together, these data imply that 
reduction in weight can ameliorate symptoms in the IIH 
patient cohort and suggest that reducing adipose tissue has 
a positive therapeutic effect on IIH.
However, the relationship between obesity and IIH is 
complex. The degree of weight loss does not correlate directly 
with the reduction in ICP.12 Furthermore, it is also important 
to note that 29%–50% of IIH patients do not gain any weight 
prior to their disease onset.3,11 The weight threshold for devel-
oping IIH may be patient specific.
How obesity leads to IIH is uncertain but a number of 
suggestions have been made. A study by Sugerman et al 
suggested that central obesity raises intra-abdominal 
pressure, which increases cardiac filling pressure and 
thereby obstructs venous return from the brain, subse-
quently leading to increased intracranial venous pressure 
and the raised ICP associated with IIH.18 However, not 
all obese patients have intracranial hypertension. There is 
only a weak positive association between lumbar puncture 
pressure and BMI.19,20 In addition, the CSF pressure in 
the general population itself can range widely from 6 to 
28 cmCSF.21
The distribution of adipose tissue may play a role in the 
development of IIH. A small cohort study reported a lower 
waist-to-hip ratio in IIH patients compared with non-IIH 
obese subjects. This suggests a relationship with lower 
body adiposity compared with other obesity-related condi-
tions, for example, diabetes mellitus, metabolic syndrome, 
and hypertension, which are associated largely with central 
adiposity.22 Further evaluation of anthropological measures 
in IIH is needed to confirm this finding.
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is a condition associated with 
both obesity and IIH. It has been implicated as a causative 
factor in IIH, especially in men.23 OSA could lead to raised 
ICP through a dual mechanism: raised venous pressure 
owing to higher intrathoracic pressure and cerebral vaso-
dilation secondary to nocturnal hypoxia and hypercapnia.24 
It is well recognized that in those patients with raised ICP 
and significant OSA, treating the nocturnal hypoxia with 
continuous positive airway pressure can effectively treat the 
intracranial hypertension in some patients. However, obesity 
is a risk factor for OSA, and its concurrence with IIH may be 
merely a coincidence. In addition, many IIH patients do not 
suffer from OSA, and therefore, it is unlikely to be a major 
causative factor.
Inflammation
Adipose tissue is a potent endocrine organ secreting a spec-
trum of molecules, including adipokines and cytokines. Later, 
we discuss which of these have been studied in IIH.
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Adipokines
Adipokines are a type of cytokine that is produced predomi-
nantly by the adipose tissue and include ghrelin, resistin, 
adiponectin, and leptin. Of these, leptin has been the 
main focus of IIH research. In particular, adiponectin and 
resistin have not found to be significantly different in the 
serum and CSF of IIH when age, sex, and BMI have been 
taken into account.25
Clinical studies evaluating the levels of leptin in both 
serum and CSF in IIH have provided conflicting results. 
Serum leptin was measured in women with IIH (n=15) 
compared with obese (n=16) and lean controls (n=15). There 
were significantly higher levels of leptin in the IIH group 
(P,0.0001), and while there was a correlation with BMI 
in the control groups (P,0.0006), this was not observed in 
IIH when matched for age, sex, and weight. The differences 
in leptin levels between the cohorts may have been due to 
varying BMIs between the groups.26 A further study looked 
at paired serum and CSF samples in 26 IIH patients and 
62 controls with other neurological diagnoses. CSF leptin 
was found to be significantly higher in IIH versus age, sex, 
and BMI-matched controls (P=0.001). Once again, leptin 
levels in both serum (r=0.34; P=0.007) and CSF (r=0.51; 
P,0.0001) correlated with BMI, apart from that in the IIH 
group.25 However, two more, albeit slightly smaller, studies 
found no difference between CSF leptin in IIH participants 
and controls.27,28
Leptin itself is a 16 kDa hormone that is encoded by 
the Ob gene and has been shown to have a wide variety of 
roles, including modulation of bone formation,29 initiation 
of puberty,30 and involvement in the immune response.31 
However, its primary role is in appetite and weight regulation 
and as an indicator of energy stores within the body,32 as it 
is produced proportionally to triglyceride stores.33 Leptin 
signal transduction occurs via the leptin receptor (Ob-R), of 
which there are six known isoforms found to be distributed 
throughout the body. The long form of the receptor or Ob-Rb 
is expressed highly in the hypothalamus, particularly in the 
arcuate, ventromedial, dorsal medial, and paraventricular 
nuclei where leptin acts as an appetite signal.34 The short 
forms of the receptor are more involved in the transport of 
leptin, for example, across the blood–CSF barrier.35 In the 
brain, high levels of Ob-R gene expression have been shown 
in the choroid plexus, leptomeninges, and blood vessels, indi-
cating that leptin binding and internalization occurs at these 
locations.36 The role of leptin receptors in the choroid plexus 
has not been fully evaluated but may be key in transporting 
leptin into the CSF.
Under physiological conditions, when levels of leptin 
are high, signaling in the hypothalamus results in decreased 
appetite and increased energy expenditure, leading to weight 
loss. The opposite is true when the levels are low, and it is 
for this reason that leptin is often referred to as the satiety 
hormone due to its role in energy homeostasis.
Leptin’s role in obesity has been highlighted in animal 
models. The leptin gene knockout (ob/ob) mouse model 
demonstrates hypoleptinemia, while the leptin Ob-Rb recep-
tor deficient (db/db) mouse model reversely shows hyper-
leptinemia. However, both display an obese phenotype and 
hyperglycemia due to insulin resistance.37
Thus, it is possible that dysregulation of leptin signaling 
could lead to inappropriate weight gain, and indeed, there is 
a wealth of evidence linking leptin with obesity. In studies of 
IIH patients, preferentially high levels of leptin were noted in 
the CSF.25 It would be expected that high leptin levels in the 
CSF would reduce satiety and consequently weight in IIH; 
yet, these patients remain obese. Hence, the possibility of 
central leptin resistance in IIH has been suggested.
It is also interesting that serum leptin exhibits sexual 
dimorphism, with levels higher in women than in men.38–40 
The relevance to the predominantly female condition of IIH 
is not established.
It is not clear how dysregulation of leptin in IIH influ-
ences ICP balance. Leptin does exert effects on Na+/K+ 
ATPase channels in the kidney, and this channel is a major 
driver for CSF secretion in the choroid plexus. It was 
shown that acute dosing of leptin in animal models led 
to decreased Na+/K+ ATPase activity resulting in reduced 
natriuresis in the kidney.41 Interestingly, long-term admin-
istration of leptin, representing a chronically elevated state 
led to increased Na+/K+ ATPase activity in proximal tubule 
cells within the renal system, probably suggesting a leptin-
resistant state.41 As the choroid plexus is very similar to the 
renal proximal tubules in terms of function and epithelial 
ultrastructure,42 a chronic elevation in leptin may drive 
Na+/K+ ATPase activity in epithelial choroid plexus cells 
resulting in increased CSF secretion and hence raised ICP 
(Figure 1). Therefore, leptin could have a role in modulating 
ICP through increased CSF secretion. Further research is 
needed before clear conclusions can be drawn.
Cytokines and inflammation
Cytokines are small proteins involved in cell signaling that 
have a role in many inflammatory conditions. A number 
of studies have evaluated the cytokine profile in IIH 
(Table 1).
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One study involving 26 IIH patients and 62 nonmatched 
controls assessed the differences in a range of cytokines in 
serum and CSF. These included interleukin-1β (IL-1β), IL-6, 
IL-8, tumor necrosis factor-α, hepatocyte growth factor, 
nerve growth factor, and chemokine ligand 2, also known as 
monocyte chemotactic protein 1. The results from this study 
showed no significant differences in the cytokines tested.25
Differing results were found in a comparison of IIH 
(n=26) with multiple sclerosis (MS; n=13) and healthy 
controls (n=20). In the serum and CSF of IIH patients, 
there were a number of raised cytokines. Tumor necrosis 
factor-α was found to be elevated in the serum but not in the 
CSF when compared with the MS cohort.43 An alternative 
study demonstrated that chemokine ligand 2 was signifi-
cantly raised (P,0.01) in the CSF of IIH when adjusted for 
BMI. However, the cohorts were small consisting of eight 
patients per group.27
These studies are limited by small numbers, variable sensi-
tivities of the cytokine assays, and inconsistent control groups. 
However, the results could be suggestive of an inflammatory 
phenotype in IIH. Further studies are needed with larger IIH 
patient cohorts and, most importantly, healthy BMI-matched 
control cohorts for comparison. The mechanism by which 
cytokines alter ICP has not been explored to date.
Thrombotic factors
A prothrombotic state has also been noted in IIH patients, 
and the obesity-driven low-grade inflammation could lead 
to a hypercoagulable state in these patients.44 In a study 
of thrombotic factors in 51 IIH patients, elevated levels of 
factors VIII, IX, and XI, fibrinogen, and d-dimer were found. 
These were elevated in IIH patients who were obese compared 
with nonobese but only factor IX and fibrinogen positively 
correlated with BMI. It is possible that microthrombosis may 
block the arachnoid granulations or distal venous circulation 
impeding CSF drainage in IIH.
Steroid hormones
Sex steroids
IIH is predominantly seen in obese females of childbearing 
age; therefore, it is possible that female steroid hormones 
Blood
Epithelial choroid
plexus cell CSF
AQP1
LeptinLeptin
Basolateral
membrane
Apical
membrane
Ob-R
ATPase
H2O H2O
Acutely high
inhibits Na+
transport
Chronically high
promotes Na+
transport
Na+
K+
Figure 1 Proposed mechanism for the role of leptin in CSF secretion.
Notes: Leptin is transported into the choroid plexus via the Ob-R receptor. 
Acutely high levels of leptin result in decreased sodium (Na+) transport by Na+/K+ 
ATPase resulting in reduced movement of water (through AQP1 channels) along the 
osmotic gradient. Chronically high levels of leptin has an opposing effect resulting in 
increased Na+ movement into the CSF, consequently increasing water movement in 
the same direction and increasing iCP.
Abbreviations: AQP1, aquaporin 1; CSF, cerebrospinal fluid; ICP, intracranial 
pressure.
Table 1 Summary of differences in adipokines and cytokines 
between iiH and controls
Cytokine/adipokine CSF References Serum References
Leptin ↑ 25 ↑ 26
– 28
27
Adiponectin ↓ 25 ↓ 25
Ghrelin – 81
CCL7 ↑ 27
CCL8 ↑ 27
CCL2/MCP1 ↑ 27
- 25
iFN-γ ↑ 82 ↑ 43
43
iL-1α ↑ 27
iL-1β - 25 ↑ 82
82
iL-2 ↑ 25
iL-4 ↑ 82 ↑ 43
43
- 25
iL-6 ↑ 83
iL-10 ↑ 82 ↑ 43
43
- 83
iL-12 ↑ 43 ↑ 43
iL-17 ↑ 82 ↑ 43
43
TNF-α ↑ 25 - 43
Notes: - denotes no significant difference, ↑ denotes raise in iiH, and ↓ denotes 
decrease in IIH. There was no significant difference between IIH and controls for 
iL-8, HGF, NGF, OPN, PA1, and TGF-β in either the CSF or serum.25,82
Abbreviations: CCL, chemokine ligand; CSF, cerebrospinal fluid; HGF, hepatocyte 
growth factor; iFN, interferon; iiH, idiopathic intracranial hypertension; iL, interleukin; 
MCP1, monocyte chemotactic protein 1; NGF, nerve growth factor; TGF-β, 
transforming growth factor; TNF-α, tumor necrosis factor-α; OPN, Osteopontin: PAi, 
Plasminogen activator inhibitor 1.
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have a pathogenic role. However, a distinctive hormonal 
profile has not yet been described in IIH.
Case reports have suggested a link between the develop-
ment of pseudotumor cerebri and oral contraceptives,45,46 as 
well as pregnancy, although the latter may also be associated 
with weight gain.47 These cases suggest a potential role for 
female sex hormones in IIH.
Increased levels of estrone have been demonstrated in the 
CSF of IIH patients compared with controls. However, no 
definitive conclusions could be made as the sample numbers 
in each of the studies were too low (n=548 and n=749). In one 
study, around half of the IIH patients were male,48 and in 
addition, the women’s menstrual cycle did not appear to be 
taken into account for either study.48,49
A larger study (n=51) that assessed the hormone pro-
file of female IIH patients demonstrated no difference in 
the levels of estradiol, follicular-stimulating hormone, 
luteinizing hormone, or prolactin. The study did show 
raised levels of androgens, including testosterone and 
androstenedione, in young onset (,25 years of age) female 
patients with IIH.50
It is not clear how sex hormones could alter ICP, but inter-
estingly, studies in rabbits have demonstrated that estrogen 
and progesterone are able to reduce CSF secretion by the 
choroid plexus, on their own and in combination.51
Between 39% and 57% of IIH patients also suffer from 
polycystic ovarian syndrome (PCOS),52,53 which is character-
ized by androgen dysregulation.54 Hyperandrogenism in IIH 
needs to be further characterized and compared with PCOS 
and obese control cohorts, but it is possible that androgens 
could also play an important role in IIH etiology.
It is likely that a complex relationship between sex hor-
mones and other factors such as obesity contribute to IIH. 
Newer hypotheses seek to connect a more multifaceted 
neuroendocrine mechanism with the adipose state.
Glucocorticoids and 11β-hydroxysteroid 
dehydrogenase
In 2012, a theory unifying various effects on the mineralo-
corticoid receptor was proposed by Salpietro et al to explain 
a possible mechanism for increased CSF production and 
hence ICP in secondary IIH.55 The theory describes that 
stimulation of the mineralocorticoid receptors in the choroid 
plexus epithelium increases the activity of Na+/K+ ATPase, 
an active transporter of sodium for potassium ions. Thus, 
the movement of sodium ions into the cerebral ventricles 
increases, creating an osmotic gradient to drive CSF secre-
tion and increase ICP.55
Corticosteroids (mineralocorticoids and glucocorticoids) 
have also been implicated in IIH. Addison’s disease is an 
endocrine disorder where the adrenal glands do not pro-
duce sufficient corticosteroids,56 and the use of exogenous 
glucocorticoids, particularly their withdrawal,57,58 has been 
found to result in secondary IIH. There have been conflict-
ing reports that exogenous systemic corticosteroids show 
an acute reduction in CSF secretion at the choroid plexus in 
rabbits59 and dogs,60 but not rhesus monkeys.61 The lack of 
chronic efficacy and multiple side effects, including weight 
gain, means that corticosteroids are not recognized as a treat-
ment option in IIH.
Glucocorticoids are steroid hormones with a wide 
range of physiological roles in the human body, including 
effects to the immune system, wound healing, metabolism 
such as gluconeogenesis and lipolysis, fetal development, 
and CNS maturation.62 The predominant glucocorticoid 
produced by the human adrenal glands is cortisol. Systemic 
levels of cortisol are regulated by the hypothalamic–pitu-
itary–adrenal (HPA) feedback system (Figure 2).
However, at a cellular specific level, the availability 
of active cortisol is regulated by 11β-hydroxysteroid 
dehydrogenases (11β-HSDs). 11β-HSDs are intracellular 
enzymes involved in the bidirectional conversion of cel-
lular glucocorticoids. Recently, there has been increasing 
interest regarding 11β-HSD type 1 (11β-HSD1) in rela-
tion to obesity, diabetes mellitus type 2, and metabolic 
syndrome.
Hypothalamus
Pituitary
Adrenal
CortisolKidney
ACTH
CRH
Figure 2 Hypothalamic–pituitary–adrenal axis.
Notes: The hypothalamus releases CRH when systemic cortisol is low. CRH stimulates 
the pituitary gland to release ACTH, which in turn stimulates the adrenal gland to release 
cortisol. Cortisol leads to a negative feedback loop by inhibiting release of CRH and 
ACTH. Black arrows stimulate release and red lines inhibit release.
Abbreviations: ACTH, adrenocorticotrophin hormone; CRH, corticotrophin-
releasing hormone.
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11β-HSD has two isozymes (Figure 3): 11β-HSD1, which 
acts in a predominately oxoreductase fashion in vivo to convert 
inactive cortisone to active cortisol, and 11β-HSD2 that is 
principally a dehydrogenase, reversing the reaction in tissues 
such as the kidney and placenta where high glucocorticoid lev-
els could inappropriately activate mineralocorticoid receptors. 
Inappropriate activation of these receptors by cortisol results 
in hypertension, hypokalemia, and hypernatremia.63 Hexose-
6-phosphate dehydrogenase colocalizes with 11β-HSD164 at 
the endoplasmic reticulum65 and provides energy in the form 
of nicotinamide adenine dinucleotide phosphate (NADPH) 
to the oxidized form NADP+.
11β-HSD1 activity is highest in hepatic and adipose 
tissue66 but has also been identified in the brain, in particular 
the cerebellum, neocortex, hippocampus, choroid plexus, 
and arachnoid granulations.67,68 Interestingly, 11β-HSD1 and 
key elements of the glucocorticoid signaling pathway have 
been found to be expressed and functional (increasing local 
cortisol availability) in the choroid plexus.68,69 It is possible 
that this local cortisol generating system could drive CSF 
secretion at the choroid plexus epithelium.68
Systemic administration of glucocorticoids can modify 
the activity of 11β-HSD1 further altering local tissue active 
cortisol availability. The effects of cortisol on 11β-HSD1 
activity are both tissue and species specific, for example, 
dexamethasone can reduce 11β-HSD1 activity in rat liver 
and testis, thereby reducing local cortisol availability.70 
In other tissues, exogenous glucocorticoids can activate 
11β-HSD1. Consequently, treatment or withdrawal of sys-
temic glucocorticoids may influence 11β-HSD1-dependent 
cortisol generation at the choroid plexus and in turn impact 
on CSF secretion.
11β-HSD1 and obesity
11β-HSD1 is dysregulated in obesity. Mice overexpress-
ing global 11β-HSD1 demonstrate features of metabolic 
syndrome with visceral obesity, glucose intolerance, and 
dyslipidemia.71 Overexpression specifically in the liver 
(apoE-HSD1 transgenic model) lacks the glucose intol-
erance and obesity seen in the global expression model, 
suggesting that production of 11β-HSD1 in another tissue 
must be responsible for the increased weight.72 Conversely, 
overexpression solely in adipose tissue, known as the aP2 
HSD1 transgenic model, drives a phenotype of metabolic 
syndrome.71 This suggests a role for adipose-derived 11β-
HSD1 in the development of a metabolic syndrome. Knock-
out mice for 11β-HSD1 have improved glucose tolerance, 
hepatic sensitization to insulin, hyperglycemia resistance, 
and lower triglyceride levels but with associated adrenal 
hyperplasia.73
Obesity in human beings is associated with normal 
systemic cortisol levels but increased 11β-HSD1 expres-
sion and activity in subcutaneous fat.74 11β-HSD1 activity, 
measured by urinary cortisol metabolites, is also dysregulated 
in obesity.75 However, after a weight loss intervention in 12 
healthy obese patients, there were no changes in global mark-
ers of 11β-HSD1 activity, which would have been expected 
with a reduction in adipose mass.76
11β-HSD1 and iiH
During a low calorie diet in IIH, while systemic cortisol 
levels remained within normal levels, urinary cortisol 
metabolites decreased (P=0.001) with substantial weight 
loss (15⋅7 kg [standard deviation {SD} 8.0], P,0.001) and 
global 11β-HSD1 activity was significantly reduced, corre-
lating (r=0.504; P=0.028) with a fall in ICP (8 cmH
2
O [SD 
4.2], P,0.001). In addition, after the weight loss interven-
tion, papilledema and headaches also improved significantly. 
Furthermore, increases in CSF cortisone levels, suggesting 
decreased 11β-HSD1 activity, correlated with weight loss.69 
Given the relationship between 11β-HSD1 and ICP, inhibitors 
of this enzyme could play a therapeutic role in IIH.
O
O O
OO
OH OH
OH
OH
OH NADPH NADP+
11β-HSD1
11β-HSD2
H
Cortisone Cortisol
H H
HHH
Figure 3 11β-HSDs and GR conversion.
Abbreviation: 11β-HSDs, 11β-hydroxysteroid dehydrogenases; GR, glucocorticoid; NADPH, nicotinamide adenine dinucleotide phosphate.
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Inhibition of 11β-HSD1 has been shown to decrease 
intraocular pressure in ocular hypertension.77 The ocular 
ciliary epithelium, responsible for producing aqueous humor 
in the eye, has the same embryological origin as the choroid 
plexus and both tissues have an analogous mechanism for 
fluid secretion. Akin to ICP, pressure within the eye is depen-
dent on the balance between aqueous secretion from the cili-
ary body and drainage through the trabecular meshwork and 
scleral pathways. Within the ciliary body, cortisol has been 
shown to activate the glucocorticoid receptors resulting in 
increased serum- and glucocorticoid-regulated kinase type 1 
(sgk1), subsequently driving sodium channels, such as Na+/K+ 
ATPase. Transport of sodium ions creates an osmotic gradient 
that leads to fluid transport, and thus aqueous humor produc-
tion.77 Therefore, selective inhibition of 11β-HSD1 could also 
be effective at reducing raised ICP by reducing fluid secretion 
at the choroid plexus via inactivation of the glucocorticoid 
signaling pathway (Figure 4). In addition, it may be disease 
modifying by ameliorating the features of a metabolic profile 
such as improving glycemic control and decreasing weight.
inhibition of 11β-HSD1
Liquorice is a naturally existing, nonselective 11β-HSD 
inhibitor. Excessive consumption can lead to an apparent 
mineralocorticoid excess presenting with hypertension, 
hypokalemia, and hypernatremia. However, the levels of 
circulating mineralocorticoids, and its upstream stimulatory 
hormone renin, are in fact low. This occurs as 11β-HSD2 
is inhibited allowing glucocorticoids to occupy miner-
alocorticoid receptors resulting in activation of the renin– 
angiotensin–aldosterone pathway.
Derivatives of liquorice, including glycyrrhetinic acid 
and carbenoxolone, have both been used experimentally 
as nonselective inhibitors of 11β-HSD. Studies evaluating 
nonselective inhibitors in mice and nonobese diabetic human 
beings have demonstrated lowered plasma glucose but a 
concomitant increase in blood pressure and potassium.78,79 
Also, carbenoxolone appeared poorer at subcutaneous fat 
inhibition in obese compared with lean subjects.74
There has been a focus to develop 11β-HSD1 selective 
inhibitors in recent years aimed at treating obesity, metabolic 
syndrome, and diabetes mellitus type 2.80 As the metabolic 
syndrome profile has a greater association with adipose 
11β-HSD1 in mice, it appears that an effective 11β-HSD1 
inhibitor should be both isozyme-selective and effective in 
the adipose tissue.
A current Medial Research Council-funded study due to 
finish in 2017, is assessing a selective competitive inhibitor 
of 11β-HSD1, AZD4017, and its effects on the ICP in IIH 
(ClinicalTrials.gov Identifier: NCT02017444). The results 
may offer further answers regarding the role 11β-HSD1 may 
play in raised ICP and IIH.
Conclusion
Obesity is strongly related to the development of IIH but it is 
not a lone factor; otherwise, a greater proportion of the obese 
population would be expected to develop this condition. The 
mechanism behind weight gain in IIH and its association 
with raised ICP remains a debated issue. Adipose tissue has 
been increasingly viewed as a neuroendocrine tissue releas-
ing chemical signals, in particular adipokines such as leptin, 
which could act directly on the choroid plexus or arachnoid 
granulation tissue, or indirectly via peripheral mechanism 
with consequent secondary central effects that modify CSF 
secretion and absorption. How this tissue is distributed in 
IIH and the role it may have in disease development requires 
further investigation.
The obese state is also an inflammatory condition where 
chronically increased circulating or CSF cytokines may result 
in fibrotic changes or lead to a hypercoagulable state caus-
ing blockage of the arachnoid granulations and, therefore, 
reducing drainage of CSF.
Blood
Cortisone Cortisone → cortisol
Epithelial choroid
plexus cell CSF
GR/MR
*?sgk1
11β-HSD1
Basolateral
membrane
Apical
membrane
AQP1
ATPase
ENaC
H2O
Na+
Na+
K+
Figure 4 Proposed mechanism for CSF secretion through a GR signaling pathway.
Notes: within the choroid plexus epithelial cell, cortisone is converted to cortisol 
by 11β-HSD1. Cortisol in turn binds to either the GR or the MR. Activation of these 
receptors activates transcription factors such as serum- and GR-regulated kinase type 
1 (sgk1) to upregulate the Na+/K+ ATPase and eNaC. Movement of sodium into the 
CSF creates an osmotic gradient allowing movement in the same direction through 
water channels such as AQP1. *Other transcription factors may be involved.
Abbreviations: AQP1, aquaporin 1; 11β-HSD1; 11β-hydroxysteroid dehydrogenase 
type 1; CSF, cerebrospinal fluid; ENaC, epithelial sodium channels; GR, glucocorticoid; 
MR, mineralocorticoid receptor.
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The epidemiology of comorbidities such as OSA and 
PCOS needs to be defined regarding any involvement they 
may have in the IIH disease process. In particular, comparing 
the hyperandrogenism profile observed in IIH with a PCOS 
and healthy obese cohort may reveal further clues regarding 
the role of hormones in IIH.
The evidence supporting the role of female sex steroids is 
still lacking, but observationally, the clear female bias for IIH 
suggests they may be involved. Glucocorticoids had originally 
been shown to have a role anecdotally in IIH. However, as 
the systemic levels of cortisol and other glucocorticoids are 
normal in IIH, there has been a shift to look at cellular steroid 
regulation. Following a low-calorie dietary intervention in IIH, 
there was a significant weight loss and an associated reduction 
in ICP. In conjunction, a decrease in global 11β-HSD1 activity 
was observed following the intervention. 11β-HSD1 has also 
shown a role in ocular pressure through effects to fluid secre-
tion into the eye. The role 11β-HSD1 may play is potentially 
important in the development of raised ICP in IIH and obesity. 
A current trial assessing the impact of an 11β-HSD1 inhibitor 
on ICP in IIH should clarify this role in the future.
Currently, the treatment options for IIH are limited owing 
to a lack of knowledge surrounding the pathogenesis of the 
condition. Therefore, the underlying mechanisms behind IIH 
remain uncertain. This review has outlined hormonal and 
obesity-related factors that may have a role in IIH includ-
ing a potential new pathogenic mechanism involving the 
11β-HSD1 enzyme and cellular glucocorticoids. Further 
basic and clinical research is required in these areas to con-
firm or refute their involvement.
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